KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Net Margin (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Net Margin data on record, last reported at 6.09% in Q4 2025.

  • For Q4 2025, Net Margin rose 893.0% year-over-year to 6.09%; the TTM value through Dec 2025 reached 4.24%, up 688.0%, while the annual FY2025 figure was 4.24%, 842.0% up from the prior year.
  • Net Margin reached 6.09% in Q4 2025 per AMRX's latest filing, up from 2.31% in the prior quarter.
  • Across five years, Net Margin topped out at 6.09% in Q4 2025 and bottomed at 21.6% in Q2 2022.
  • Average Net Margin over 5 years is 1.29%, with a median of 0.46% recorded in 2021.
  • Peak YoY movement for Net Margin: tumbled -2431bps in 2022, then surged 2359bps in 2023.
  • A 5-year view of Net Margin shows it stood at 1.19% in 2021, then skyrocketed by 40bps to 0.71% in 2022, then crashed by -2028bps to 15.12% in 2023, then soared by 81bps to 2.84% in 2024, then skyrocketed by 314bps to 6.09% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 6.09% in Q4 2025, 2.31% in Q3 2025, and 4.92% in Q2 2025.